BRAF and mucosal melanoma: When BRAF V600E-mutant metastatic or unresectable mucosal melanoma (N = 12) patients were treated in a small study with BRAF inhibitors with or without a MEK inhibitor, the ORR was 20%, and DCR was 70% [40].